Evidence map›Paper›PMID 29069750›Full record

ArticleOncotarget2017

AG488 as a therapy against gliomas.

Jadith Ziegler, Anja Bastian, Megan Lerner, Lora Bailey-Downs, Debra Saunders, Nataliya Smith, Jake Sutton, James D Battiste, Michael A Ihnat, Aleem Gangjee and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jadith ZieglerAdvanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Anja BastianDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Megan LernerDepartment of Surgery Research Laboratory, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Lora Bailey-DownsDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Debra SaundersAdvanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Nataliya SmithAdvanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Jake SuttonAdvanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
James D BattisteStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Michael A IhnatDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Aleem GangjeeGraduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA, USA.
Rheal A TownerAdvanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Oklahoma Medical Research Foundation · USUniversity of Oklahoma Health Sciences Center · USDuquesne University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-grade gliomas such as glioblastomas (GBM) present a deadly prognosis following diagnosis and very few effective treatment options. Here, we investigate if the small molecule AG488 can be an effective therapy against GBM with both anti-angiogenic as well as an anti-microtubule inhibiting modalities, using a human G55 glioma xenograft model in nude mice. From

Indexed as

angiogenesisanti-cancer therapygliomasin vivomagnetic resonance imaging (MRI)

Identifiers

PMID29069750
PMCPMC5641093
OpenAlexW2619862601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.